全文获取类型
收费全文 | 26144篇 |
免费 | 2411篇 |
国内免费 | 69篇 |
专业分类
耳鼻咽喉 | 268篇 |
儿科学 | 624篇 |
妇产科学 | 371篇 |
基础医学 | 3195篇 |
口腔科学 | 839篇 |
临床医学 | 3330篇 |
内科学 | 5608篇 |
皮肤病学 | 633篇 |
神经病学 | 1881篇 |
特种医学 | 1376篇 |
外科学 | 3606篇 |
综合类 | 492篇 |
一般理论 | 24篇 |
预防医学 | 2682篇 |
眼科学 | 358篇 |
药学 | 2011篇 |
1篇 | |
中国医学 | 23篇 |
肿瘤学 | 1302篇 |
出版年
2021年 | 363篇 |
2020年 | 208篇 |
2019年 | 347篇 |
2018年 | 378篇 |
2017年 | 283篇 |
2016年 | 341篇 |
2015年 | 391篇 |
2014年 | 548篇 |
2013年 | 849篇 |
2012年 | 1136篇 |
2011年 | 1133篇 |
2010年 | 650篇 |
2009年 | 616篇 |
2008年 | 1051篇 |
2007年 | 1071篇 |
2006年 | 1100篇 |
2005年 | 1113篇 |
2004年 | 1033篇 |
2003年 | 987篇 |
2002年 | 977篇 |
2001年 | 990篇 |
2000年 | 1010篇 |
1999年 | 858篇 |
1998年 | 375篇 |
1997年 | 331篇 |
1996年 | 311篇 |
1995年 | 313篇 |
1994年 | 239篇 |
1993年 | 263篇 |
1992年 | 613篇 |
1991年 | 639篇 |
1990年 | 607篇 |
1989年 | 568篇 |
1988年 | 525篇 |
1987年 | 524篇 |
1986年 | 525篇 |
1985年 | 537篇 |
1984年 | 374篇 |
1983年 | 322篇 |
1982年 | 245篇 |
1981年 | 236篇 |
1980年 | 192篇 |
1979年 | 329篇 |
1978年 | 256篇 |
1977年 | 223篇 |
1976年 | 183篇 |
1975年 | 184篇 |
1974年 | 214篇 |
1973年 | 204篇 |
1971年 | 192篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
RA O. Hempel 《Notfall & Rettungsmedizin》2007,10(5):367-371
Legal uncertainties for emergency vehicle drivers can be avoided when fundamental rules are established. In particular, differentiation of special rights and rights of way is essential. Inherent in both is the urgency necessary to save human lives. The right of way signaled by flashing blue lights and siren does not however justify traffic violations but signifies rather a request to other traffic participants. In contrast, special rights require no announcement and constitute a justifiable reason for traffic violations. Even so they do not allow that other traffic participants be endangered or harmed. Adherence to these basic principles can prevent legal misinterpretations as well as rigid adoption of inflexible standards of behavior. 相似文献
42.
RA Mag. Dr. C. Gepart 《Notfall & Rettungsmedizin》2007,10(4):289-292
Austria’s new Living Wills Act (Patientenverfügungsgesetz, or PatVG) that came into effect on 1st of June 2006, is the first law in Austria to regulate the controversial issue of living wills. The PatVG provides for a right to refuse future medical treatment by making an advance directive in the form of a living will that is either binding or “to be taken into consideration”. However, the establishment of a binding living will is governed by strict criteria as regards form and content, and both a medical doctor and a legal expert must be involved. Compliance with a living will is not allowed where there is a legal obligation to give medical treatment. There is also a legal obligation to give medical treatment in emergency situations where the time involved in looking for a living will could seriously endanger the health or the life of a patient. 相似文献
43.
44.
45.
M. S. Reddy S. A. White B. C. Jaques N. Torpey D. M. Manas 《American journal of transplantation》2007,7(10):2422-2424
As demand for donor pancreases increases, attempts are being made to utilize even marginal grafts for transplantation. Injury during pancreas recovery can predispose to posttransplant complications and graft loss. Early recognition and correction can salvage these grafts. The authors report an instance of poor segmental perfusion of the pancreas graft that was salvaged by pancreas head resection and enteric drainage through a Roux-en-Y pancreatico-jejunostomy. 相似文献
46.
Vanaporn Wuthiekanun Varunee Desakorn Gumphol Wongsuvan Premjit Amornchai Allen C. Cheng Bina Maharjan Direk Limmathurotsakul Wirongrong Chierakul Nicholas J. White Nicholas P. J. Day Sharon J. Peacock 《Clinical and Vaccine Immunology : CVI》2005,12(4):555-556
An immunofluorescent (IF) method that detects Burkholderia pseudomallei in clinical specimens within 10 min was devised. The results of this rapid method and those of an existing IF method were prospectively compared with the culture results for 776 specimens from patients with suspected melioidosis. The sensitivities of both IF tests were 66%, and the specificities were 99.5 and 99.4%, respectively. 相似文献
47.
Patient-controlled analgesia. Does a concurrent opioid infusion improve pain management after surgery? 总被引:4,自引:0,他引:4
OBJECTIVE.--To assess the influence of a continuous (basal) morphine infusion as part of a patient-controlled analgesia (PCA) system on the postoperative analgesic requirement and on recovery parameters following abdominal hysterectomy. DESIGN.--Single-center, randomized, controlled protocol. SETTING.--University medical center. PARTICIPANTS.--A total of 230 adult women were randomly assigned to receive no morphine infusion (control group) or a continuous 0.5-, 1.0-, or 2.0-mg/h morphine infusion. Each patient was able to self-administer supplemental intravenous bolus doses of morphine (1 to 2 mg) using a PCA infuser. MAIN OUTCOME MEASURES.--Use of the PCA device, opioid-related side effects, recovery times, and the patients' assessment of pain and sedation on linear visual analog scales were recorded during the 72-hour study period. Follow-up questionnaires were completed by the patients and their health care professionals to assess the overall adequacy of PCA therapy. RESULTS.--Patients who received the 2-mg/h morphine infusions received significantly more opioid medication 9 to 72 hours after their operation than those who received no infusion (control group). The presence of a continuous morphine infusion of 0.5 to 2 mg/h did not significantly decrease the number of patient demands or supplemental bolus doses administered compared with the control group. Overall, 168 (84%) of the 199 patients who completed the 72-hour study were able to achieve adequate analgesia without requiring changes in the PCA regimen or experiencing major side effects. Recovery times and outcome variables were similar in all four groups. CONCLUSION.--The routine use of a continuous opioid infusion in combination with a standard PCA regimen does not improve pain management compared with PCA alone after abdominal hysterectomy. 相似文献
48.
49.
G C Palmer M L Stagnitto J M Ordy R C Griffith J J Napier R J Gentile J H Woodhead H S White E A Swinyard 《Epilepsy research》1991,8(1):36-48
Stereoisomers of remacemide (racemate form) were compared for anticonvulsant efficacy and safety in mice. In the maximal electroshock seizure (MES) test for oral efficacy, the (-) stereoisomer, FPL 14145, was more potent than the racemate or the (+) stereoisomer, FPL 14144. Respective ED50 values (expressed as mg/kg) were: remacemide, 58; FPL 14145, 45; FPL 14144, 79. In 2 of 3 tests for neural impairment, FPL 14145 yielded significantly better therapeutic indices (toxic dose 50/ED50) than the racemate. The margin of safety (estimated median lethal dose ED50) was more favorable for FPL 14144: remacemide, 15.1; FPL 14144, 18.9; FPL 14145, 15.7. The duration of protection against MES indicated the stereoisomers were longer acting than the racemate. After intravenous administration the order of potency against MES was similar: FPL 14145 greater than remacemide greater than FPL 14144. Following daily administration of the oral ED98 for 4 days, with a dose response curve run on day 5, the MES ED50 values for all compounds were increased. The test indicates tolerance. In the pentylenetetrazol infusion test the racemate and FPL 14144 demonstrated more proconvulsant properties than FPL 14145. Intraperitoneal administration of 50 mg/kg or more produced changes in behavior with all compounds. At higher doses the racemate and FPL 14145 elicited more severe symptoms with death at 200 mg/kg. 相似文献
50.